EP0584251A4 - Cytokine receptor targeted molecules for treatment of meoplastic cell growth. - Google Patents

Cytokine receptor targeted molecules for treatment of meoplastic cell growth.

Info

Publication number
EP0584251A4
EP0584251A4 EP92912726A EP92912726A EP0584251A4 EP 0584251 A4 EP0584251 A4 EP 0584251A4 EP 92912726 A EP92912726 A EP 92912726A EP 92912726 A EP92912726 A EP 92912726A EP 0584251 A4 EP0584251 A4 EP 0584251A4
Authority
EP
European Patent Office
Prior art keywords
meoplastic
treatment
cell growth
cytokine receptor
targeted molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912726A
Other languages
German (de)
French (fr)
Other versions
EP0584251A1 (en
Inventor
Cory Ann Waters
Louis R Poisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seragen Inc
Original Assignee
Seragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seragen Inc filed Critical Seragen Inc
Publication of EP0584251A1 publication Critical patent/EP0584251A1/en
Publication of EP0584251A4 publication Critical patent/EP0584251A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP92912726A 1991-05-17 1992-05-15 Cytokine receptor targeted molecules for treatment of meoplastic cell growth. Withdrawn EP0584251A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70193291A 1991-05-17 1991-05-17
US701932 1996-08-26

Publications (2)

Publication Number Publication Date
EP0584251A1 EP0584251A1 (en) 1994-03-02
EP0584251A4 true EP0584251A4 (en) 1995-08-02

Family

ID=24819258

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912726A Withdrawn EP0584251A4 (en) 1991-05-17 1992-05-15 Cytokine receptor targeted molecules for treatment of meoplastic cell growth.

Country Status (4)

Country Link
EP (1) EP0584251A4 (en)
JP (1) JPH06507900A (en)
CA (1) CA2103258A1 (en)
WO (1) WO1992020364A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69525971T3 (en) * 1994-12-29 2013-01-10 Chugai Seiyaku K.K. USE OF A PM-1 ANTIBODY OR AN MH 166 ANTIBODY FOR REINFORCING THE ANTI-TUMOR EFFECT OF CISPLATINE OR CARBOPLATIN
JP2003501402A (en) * 1999-06-03 2003-01-14 バイオイノベイション・リミテッド Gene therapy products
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
WO1991002000A1 (en) * 1989-08-02 1991-02-21 Seragen, Inc. Il-2 deletion mutants
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082927A (en) * 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5084556A (en) * 1987-10-23 1992-01-28 Genetics Institute, Inc. Composition of M-CSF conjugated to cytotoxic agents and a method for treating cancers characterized by over-expression of the c-fms proto-oncogene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001004A1 (en) * 1989-07-06 1991-01-24 Seragen, Inc. Hybrid molecules
WO1991002000A1 (en) * 1989-08-02 1991-02-21 Seragen, Inc. Il-2 deletion mutants
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BACHA, PATRICIA A. ET AL: "Impact of interleukin -2- receptor -targeted cytotoxins on a unique model of murine interleukin -2- receptor -expressing malignancy", INT. J. CANCER (1991), 49(1), 96-101 CODEN: IJCNAW;ISSN: 0020-7136 *
C. F. LEMAISTRE ET AL.: "PHASE I-II EVALUATION OF AN IL-2 RECEPTOR TARGETED FUSION TOXIN DAB-486 IL-2 FOR TREATMENT OF AIDS-ASSOCIATED KAPOSI'S SARCOMA.", ISITITUTO SUP. DI SANITA. VII INTERNATIONAL CONFERENCE ON AIDS: SCIENCE CHALLENGING AIDS; FLORENCE, ITALY, 16 June 1991 (1991-06-16), pages 79 *
CHARLES F. LEMAISTRE ET AL.: "THERAPEUTIC EFFECTS OF GENETICALLY ENGINEERED TOXIN (DAB486IL-2) IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKAEMIA.", LANCET THE, vol. 337, 11 May 1991 (1991-05-11), LONDON GB, pages 1124 - 1125 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
NICHOLS, J. C. ET AL: "Development of IL-2-toxin ( DAB486 -IL-2) for human clinical trials in interleukin -2 receptor positive malignancies", ZENTRALBL. BAKTERIOL., SUPPL. (1990), 19(BACT. PROTEIN TOXINS), 479-87 CODEN: ZBASE2 *
See also references of WO9220364A1 *
TESUYUKI KIYOKAWA ET AL.: "PROTEIN ENGEERING OF DIPHTERIA-TOXIN-RELATED INTERLEUKIN-2 FUSION TOXINS TO INCREASE CYTOTOXIC POTENCY FOR HIGH-AFFINITY IL-2-RECEPTOR-BEARING TARGET CELLS.", PROTEIN ENGINEERING, vol. 4, no. 4, ENGLAND GB, pages 463 - 468 *

Also Published As

Publication number Publication date
EP0584251A1 (en) 1994-03-02
WO1992020364A1 (en) 1992-11-26
CA2103258A1 (en) 1992-11-18
JPH06507900A (en) 1994-09-08

Similar Documents

Publication Publication Date Title
EP0603194A4 (en) Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis.
EP0721340A4 (en) Use of cell surface receptor targeted molecules for the treatment of viral diseases
EP0576870A3 (en) Microorganism growth apparatus.
EP0639362A3 (en) Growth adjustable absorbent article.
HU9300252D0 (en) Structure for supporting vertebra
AU7344291A (en) Spine tensioning body support
EP0668774A4 (en) Interleukin receptor targeted molecules for treatment of inflammatory arthritis.
GB8728550D0 (en) Adjustable chair
GB9104021D0 (en) Adjustable pot-plant support
EP0584251A4 (en) Cytokine receptor targeted molecules for treatment of meoplastic cell growth.
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
PH31659A (en) Therapeutic nucleotides.
AU2593692A (en) Biological wastewater treatment process
EP0609358A4 (en) Methods for treatment of hyperlipidemia using azaspiranes.
AU2959892A (en) Apparatus for thermal treatment of the prostate
PL306798A1 (en) Biologically active ureide derivatives useful in treating disease being breed by lentivirus
ZA925385B (en) Seed treatment
GB9027429D0 (en) Effluent treatment
AU2518592A (en) Mutated growth factor receptor as medicament and its use for treating cancer
GB9225791D0 (en) Adjustable chair bed
EP0609335A4 (en) Methods for the treatment of hyperlipidemia using azaspiranes.
IL103451A0 (en) Adjustable orthotic
GB9108786D0 (en) Effluent treatment
AU2801092A (en) Drugs for treating aids
AU2048592A (en) Seed treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19950615

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19970402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19971014